Salivary miRNA profiles identify children with autism spectrum disorder, correlate with adaptive behavior, and implicate ASD candidate genes involved in neurodevelopment

Steven D Hicks, Cherry Ignacio, Karen Gentile, Frank A Middleton, Steven D Hicks, Cherry Ignacio, Karen Gentile, Frank A Middleton

Abstract

Background: Autism spectrum disorder (ASD) is a common neurodevelopmental disorder that lacks adequate screening tools, often delaying diagnosis and therapeutic interventions. Despite a substantial genetic component, no single gene variant accounts for >1 % of ASD incidence. Epigenetic mechanisms that include microRNAs (miRNAs) may contribute to the ASD phenotype by altering networks of neurodevelopmental genes. The extracellular availability of miRNAs allows for painless, noninvasive collection from biofluids. In this study, we investigated the potential for saliva-based miRNAs to serve as diagnostic screening tools and evaluated their potential functional importance.

Methods: Salivary miRNA was purified from 24 ASD subjects and 21 age- and gender-matched control subjects. The ASD group included individuals with mild ASD (DSM-5 criteria and Autism Diagnostic Observation Schedule) and no history of neurologic disorder, pre-term birth, or known chromosomal abnormality. All subjects completed a thorough neurodevelopmental assessment with the Vineland Adaptive Behavior Scales at the time of saliva collection. A total of 246 miRNAs were detected and quantified in at least half the samples by RNA-Seq and used to perform between-group comparisons with non-parametric testing, multivariate logistic regression and classification analyses, as well as Monte-Carlo Cross-Validation (MCCV). The top miRNAs were examined for correlations with measures of adaptive behavior. Functional enrichment analysis of the highest confidence mRNA targets of the top differentially expressed miRNAs was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID), as well as the Simons Foundation Autism Database (AutDB) of ASD candidate genes.

Results: Fourteen miRNAs were differentially expressed in ASD subjects compared to controls (p <0.05; FDR <0.15) and showed more than 95 % accuracy at distinguishing subject groups in the best-fit logistic regression model. MCCV revealed an average ROC-AUC value of 0.92 across 100 simulations, further supporting the robustness of the findings. Most of the 14 miRNAs showed significant correlations with Vineland neurodevelopmental scores. Functional enrichment analysis detected significant over-representation of target gene clusters related to transcriptional activation, neuronal development, and AutDB genes.

Conclusion: Measurement of salivary miRNA in this pilot study of subjects with mild ASD demonstrated differential expression of 14 miRNAs that are expressed in the developing brain, impact mRNAs related to brain development, and correlate with neurodevelopmental measures of adaptive behavior. These miRNAs have high specificity and cross-validated utility as a potential screening tool for ASD.

Keywords: Biomarker; Next generation sequencing; RNA-Seq; Saliva; miRNA.

Figures

Fig. 1
Fig. 1
Differential expression and diagnostic utility of miRNAs in saliva of ASD children. a Hierarchical cluster analysis of the top 14 miRNAs. These miRNAs were differentially expressed in ASD children compared with Controls. Color indicates average Z-score of normalized abundance for each gene. A Euclidian distance metric was used with average cluster linkages for this figure. b Partial Least Squares Discriminant Analysis (PLS-DA) of the top 14 miRNAs showed the general separation of subjects into two clusters, using only three eigenvector components (x, y, and z axes labeled Component 1, Component 2, and Component 3) that collectively accounted for 55 % of the variance of the data set. c ROC-AUC analysis of the training data set indicated a very high level of performance in the logistic regression classification test (100 % sensitivity, 90 % specificity, with an AUC of 0.97)
Fig. 2
Fig. 2
Monte-Carlo Cross-Validation analysis of the top 14 miRNAs. a The robustness of the 14 miRNA biomarkers was evaluated in stepwise fashion by determining their ability to correctly classify subjects using 100 iterations of a multivariate PLS-DA with 2, 3, 5, 7, 10, and 14 miRNAs included, and masking of 1/3 of the subjects during the training phase. This revealed an overall ROC-AUC of 0.92 and mis-classification of three ASD and four Control subjects. b Shows the classification of subjects plotted by predicted class probabilities from the MCCV (x axis), with incorrectly classified subjects identified by ID number. The y axis units are arbitrary. c Whisker box plots (showing median and inter-quartile range) of the four most robustly changed miRNAs according to the Mann-Whitney test

References

    1. Harrington JW, Allen K. The Clinician’s guide to autism. Pediatr Rev. 2014;35:62–77. doi: 10.1542/pir.35-2-62.
    1. Wetherby AM, Brosnan-Maddox S, Peace V, Newton L. Validation of the Infant-Toddler Checklist as a broadband screener for autism spectrum disorders from 9 to 24 months of age. Autism. 2008;12:487–511. doi: 10.1177/1362361308094501.
    1. Robins DL. Screening for autism spectrum disorders in primary care settings. Autism. 2008;12:537–556. doi: 10.1177/1362361308094502.
    1. Rosenberg RE, Law JK, Yenokyan G, McGready J, Kaufmann WE, Law PA. Characteristics and concordance of autism spectrum disorders among 277 twin pairs. Arch Pediatr Adolesc Med. 2009;163:907–914. doi: 10.1001/archpediatrics.2009.98.
    1. Constantino JN, Todorov A, Hilton C, Law P, Zhang Y, Molloy E, Fitzgerald R, Geschwind D. Autism recurrence in half siblings: strong support for genetic mechanisms of transmission in ASD. Mol Psychiatry. 2013;18:137–138. doi: 10.1038/mp.2012.9.
    1. Xu LM, Li JR, Huang Y, Zhao M, Tang X, Wei L. Autism: an evidence-based knowledgebase of autism genetics. Nucleic Acids Res. 2012;40:D1016–D1022. doi: 10.1093/nar/gkr1145.
    1. Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet. 2012;3:1–9.
    1. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva are concentrated in exosomes. PLoS One. 2012;7:e30679. doi: 10.1371/journal.pone.0030679.
    1. Abu-Elneel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, Geschwind DH, Lao K, Kosik KS. Heterogeneous dysregulation of microRNAs across autism spectrum. Neurogenetics. 2008;9:153–161. doi: 10.1007/s10048-008-0133-5.
    1. Talebizadeh Z, Butler MG, Theodoro MF. Feasability and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res. 2008;1:1–11. doi: 10.1002/aur.46.
    1. Sarachana T, Zhou R, Chen G, Manji HK, Hu VW. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med. 2010;2:23. doi: 10.1186/gm144.
    1. Ghahramani-Seno MM, Hu P, Gwadry FG, Pinto D, Marshall CR, Casallo G, Scherer SW. Gene and miRNA expression profiles in autism spectrum disorders. Brain Res. 2011;1380:85–97. doi: 10.1016/j.brainres.2010.09.046.
    1. Vasu MM, Anitha A, Thanseem I, Suzuki K, Yamada K, Takahashi T, Wakuda T, Iwata K, Tsujii M, Sugiyama T, Mori N. Serum microRNA profiles in children with autism. Mol Autism. 2014;5:40. doi: 10.1186/2040-2392-5-40.
    1. Ziats MN, Rennert OM. Identification of differentially expressed microRNAs across developing human brain. Mol Psychiatry. 2014;19:848–852. doi: 10.1038/mp.2013.93.
    1. Shao NY, Hu HY, Xu Y, Hu H, Menzel C, Li N, Chen W, Khaitovich P. Comp-rehensive survey of human brain microRNA by deep sequencing. BMC Genomics. 2010;11:409. doi: 10.1186/1471-2164-11-409.
    1. Banerjee-Basu S, Packer A. SFARI Gene: an evolving database for the autism research community. Dis Model Mech. 2010;3:133–135. doi: 10.1242/dmm.005439.
    1. Daniels AM, Halladay AK, Shih A, Elder LM, Dawson G. Approaches to enhancing the early detection of autism spectrum disorders: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2014;53:141–152. doi: 10.1016/j.jaac.2013.11.002.
    1. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, Comery TA, Patel B, Eberwine J, Greenough WT. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A. 1997;94(10):5395–5400. doi: 10.1073/pnas.94.10.5395.
    1. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, Nelson DL, Moses K, Warren ST. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci. 2004;7:113–117. doi: 10.1038/nn1174.
    1. MacDermot KD, Bonora E, Sykes N, Coupe AM, Lai CSL, Vernes SC, Vargha-Khadem F, McKenzie F, Smith RL, Monaco AP, Fisher SE. Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits. AJHG. 2005;76(5):1074–1080. doi: 10.1086/430841.
    1. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the micro-RNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer. 2010;9:232. doi: 10.1186/1476-4598-9-232.
    1. Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K, Xu H, Jiang S. miR-24-3p and MiR27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1. Int J Oncol. 2012;42:757–766.
    1. Siefel C, Li J, Liu F, Benashski SE, McCullough LD. miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. Proc Natl Acad Sci U S A. 2011;108:11662–11667. doi: 10.1073/pnas.1102635108.
    1. Song Y, Tian X, Zhang S, Zhang Y, Li X, Li D, Cheng Y, Zhang J, Kang C, Zhao W. Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b. Brain Res. 2011;1387:134–140. doi: 10.1016/j.brainres.2011.02.073.
    1. Li Y, Xu J, Chen H, Li S, Zhao Z, Shao T, Jiang T, Ren H, Kang C, Li X. Compre-hensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression. Nucleic Acids Res. 2013;41:e203. doi: 10.1093/nar/gkt1054.
    1. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, Thiruvahindrapuram B, Xu X, Ziman R, Cook EH, Buxbaum JD, Devlin B, Gallagher L, Betancur C, Scherer SW. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet. 2014;94:677–694. doi: 10.1016/j.ajhg.2014.03.018.
    1. Geschwind DH. Genetics of autism spectrum disorder. Trends Cog Sci. 2011;15:409–416. doi: 10.1016/j.tics.2011.07.003.
    1. Chahrour MH, Yu TW, Lim ET, Ataman B, Coulter ME, Hill S, Stevens CR, Schubert CR, Greenberg ME, Gabriel SB, Walsh CA. Whole-exome sequencing and homozygosity analysis implicate depolarization-regulated neuronal genes in autism. PLoS Genet. 2012;8(4):e1002635. doi: 10.1371/journal.pgen.1002635.

Source: PubMed

3
Subskrybuj